Inclusion Criteria:
  -  Female with surgically-confirmed endometriosis, determined at laparoscopy performed within 3y prior to study baseline
  -  Age 15 years to 40 years
  -  Current use ≥ 2 months duration of hormonal therapy such as combined oral contraceptives, norethindrone acetate, or levonorgestrel intrauterine device
  -  Current pelvic pain (score ≥ 3 on Visual Analog Scale, where 0 represents absence of pain and 10 indicates unbearable pain) present for ≥ 14 days/month over the 2 months prior to study enrollment
  -  Willingness to comply with visit schedule and protocol
Exclusion Criteria:
  -  Pre-menarche or post-menopause
  -  Contraindications to cabergoline (e.g., cardiac valve disorder; pulmonary, pericardial, retroperitoneal fibrotic disorder; hypersensitivity to ergot derivatives; uncontrolled hypertension)
  -  Significant mental or chronic systemic illness that might confound pain assessment or the ability to complete the study
  -  Pregnant, breastfeeding, or planning to become pregnant in the next 6 months
  -  Impaired liver function (ALT > 2x normal) or liver disease
  -  Breast cancer, current or previous
  -  Thromboembolic disease, current or previous
  -  Use of other drugs that affect dopamine (e.g., phenothiazines, metoclopramide, butyrophenones)